Sellas Life Sciences Group Inc
(SLS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Operating Expenses | 20,041 | 31,089 | 23,039 | 15,988 | 34,220 |
| Operating Income | -20,041 | -31,089 | -23,039 | -15,988 | -34,220 |
| Interest Expense | 0 | 0 | 462 | 1,166 | 760 |
| Other Income | 668 | 2,041 | 0 | -526 | -3,611 |
| Pre-tax Income | -19,373 | -29,048 | -23,501 | -17,680 | -38,591 |
| Income Tax | -81 | -1,378 | 253 | 1 | 365 |
| Net Income Continuous | -19,292 | -27,670 | -23,754 | -17,681 | -38,956 |
| Net Income Discontinuous | N/A | N/A | N/A | N/A | -24,946 |
| Net Income | $-19,292 | $-27,670 | $-23,754 | $-17,681 | $-63,902 |
| EPS Basic Total Ops | -10.92 | -157.72 | -522.00 | -933.00 | -12,357.36 |
| EPS Basic Continuous Ops | -7.54 | -105.61 | -507.56 | -933.53 | -7,537.54 |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | N/A | -4,819.82 |
| EPS Diluted Total Ops | -10.92 | -157.72 | -522.00 | -933.00 | -12,357.36 |
| EPS Diluted Continuous Ops | -7.54 | -105.61 | -507.56 | -933.53 | -7,537.54 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | N/A | -4,819.82 |
| EPS Diluted Before Non-Recurring Items | -10.84 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-20,041 | $-21,989 | $-22,781 | $-15,985 | $-34,113 |